Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Part of paid clinical trials in Aurora, Colorado.

Sponsor
Inova Health Care Services
Study ID
NCT06532890
Status
Recruiting

Conditions

  • Cardiac Failure
  • Graft Rejection

Eligibility Criteria

Sex
ALL
Age
N/A - 18 Years
Healthy Volunteers
Not accepted

Study Details

This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.

Key Dates

Start date
Feb 6, 2025
Status verified
Aug 2025
Primary completion
Oct 1, 2029
Completion
Oct 1, 2029

Study Design

Enrollment
150 participants (estimated)

Primary Outcome Measure

Time-to-Event Analysis of Circulating microRNAs (miRs) Predicting Infection in Pediatric Heart Transplant Recipients [ Time Frame: up to 2 years post-transplant ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Children's Hospital ColoradoAuroraColorado80045
Rebecca Hill
Shelley Miyamoto, MD (PRINCIPAL_INVESTIGATOR)
University of MichiganAnn ArborMichigan48109
Christine Cislo
David Peng, MD (PRINCIPAL_INVESTIGATOR)
Columbia UniversityNew YorkNew York10032
Marc Richmond, MD (PRINCIPAL_INVESTIGATOR)
University of PittsburghPittsburghPennsylvania15224
Kyla Thorn
412-692-6061
Brian Feingold, MD (PRINCIPAL_INVESTIGATOR)
Vanderbilt UniversityNashvilleTennessee37232
Darlene Fountain
David Bearl, MD (PRINCIPAL_INVESTIGATOR)
Texas Children's HospitalHoustonTexas77030
Blake Fallon
Joseph Spinner, MD (PRINCIPAL_INVESTIGATOR)
Inova Health SystemFalls ChurchVirginia22042-

Find similar trials in Aurora, CO

Related Studies